Scleromyxedema: A case report and review of the literature

Case Reports in Dermatology

Volumn 5, Issue 2, 2013, Pages 168-175

  Allam, Mohamed ^a   Ghozzi, Mohamed ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Paraproteinemia; Scleromyxedema; Systemic sclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G LAMBDA; LOW DENSITY LIPOPROTEIN; NITROGEN; PHOSPHORUS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTHRALGIA; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DELTOID MUSCLE; DYSPHAGIA; DYSPNEA; EAR DISEASE; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGOGRAPHY; FACE RASH; FIBROSARCOMA CELL; FOLLOW UP; FOREARM; HAND RASH; HEMATOLOGY; HUMAN; LABORATORY TEST; LUNG FUNCTION TEST; MALE; MEDICAL HISTORY; MIDDLE AGED; MUSCLE WEAKNESS; NECK RASH; NEUROLOGY; OPHTHALMOLOGY; PAPULAR RASH; PAPULE; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PROXIMAL INTERPHALANGEAL JOINT; RADIODIAGNOSIS; REVIEW; SCLERODERMA; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN INDURATION; THORAX RADIOGRAPHY;

EID: 84884255215     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000353178     Document Type: Review

References (54)

1. Rongioletti F. Lichen myxedematous (papular mucinosis): new concepts and perceptives for an old disease. Semin Cutan Med Surg. 2006; 25: 100-104
2. Heymann WR. Scleromyxedema. J Am Acad Dermatol. 2007; 57: 890-891
3. Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol. 2006; 24: 493-497
4. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 1978; 199: 545-547
5. Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol. 1985; 12: 171-175
6. Chanda JJ. Scleromyxedema. Cutis. 1979; 24: 549-552
7. Bata-Csorgo Z, Husz S, Foldes M, et al. Scleromyxedema. J Am Acad Dermatol. 1999; 41: 343-346
8. Trojanowska M, Wu LT, LeRoy EC. Elevated expression of c-myc proto-oncogene in scleroderma fibroblast. Oncogene. 1988; 3: 477-481
9. Piccinini G, Luchetti MM, Canglia ML, et al. c-myc proto-oncogene is expressed by quiescent scleroderma fibroblasts and, unlike B-myc gene, does not correlate with proliferation. J Invest Dermatol. 1996; 106: 1281-1286
10. Desai AD, James WD. Lichen myxedematosus; in Lebwol MG, Heymann WR, Berth-Jones J, Coulson IC (eds): Treatment of Skin Disease: Comprehensive Therapeutic Strategies, ed 2. London, Elsevier, 2006, pp 343- 344
11. Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of literature. J Am Acad Dermatol. 1998; 38: 289-294
12. Fleming KE, Vermani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012; 39: 508-517
13. Helm F, Helm TN. Iatrogenic mylemonocytic leukemia following melphalan treatment of scleromyxedema. Cutis. 1987; 39: 219-223
14. Feldman P, Shapiro L, Pick AI, Slatkin MH. Scleromyxedema, a dramatic response to melphalan. Arch Dermatol. 1969; 99: 51-56
15. Harris RB, Perry HO, Kyle RA, Winkelmann RK. Treatment of scleromyxedema with melphalan. Arch Dermatol. 1979; 115: 295-299
16. Alligood TR, Burnett JW, Raines BL. Scleromyxedema associated with esophageal aperistalsis and dermal eosinophilia. Cutis. 1981; 28: 60-64
17. Chanda JJ. Melphalan therapy in the treatment of scleromyxedema. Arch Dermatol. 1980; 116: 862-863
18. Dinneen AM, Dicken CM. Scleromyxedema. J Am Acad Dermatol. 1995; 33: 37-43
19. Harris AO, Altman AR, Tschen JA, Wolf JE. Scleromyxedema. Int J Dermatol. 1989; 28: 661-667
20. Jessen RT, Straight M, Becker LE. Lichen myxedematosus treatment with cyclophosphamide. Int J Dermatol. 1978; 17: 833-839
21. Truhan AP, Roenigk HH. Lichen myxedematosus: an unusual case with rapid progression and possible internal involvement. Int J Dermatol. 1987; 26: 91-95
22. Dubreuilh W. Fibromes miliaires folliculaires: sclerodermie consecutive. Ann Dermatol Syph. 1906; 37: 569-572
23. Reitmann K. Über eine eigenartige, der Sklerodermie nahestehende Affektion. Arch Dermatol Syph. 1908; 92: 417-424
24. Montgomery H, Underwood LJ. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol. 1953; 20: 213-236
25. Gottron HA. Skleromyxödem (eine eigenartige Erscheinungsform von Myxothesaurodermie). Arch Dermatol. 1954; 199: 71-91
26. McCuiston SH, Schoch EP. Autopsy findings in lichen myxedematosus. Arch Dermatol. 1956; 74: 259-262
27. Rudner EJ, Mehregan A, Pinkus H. Scleromyxedema: variant of lichen myxedematosus. Arch Dermatol. 1966; 93: 3-12
28. Braun-Falco O, Weidner F. Arndt-Gottron scleromyxedema with medullary plasmacytosis and myositis (in French). Arch Belges Dermatol Syphiligr. 1970; 26: 193-217
29. Farmer ER, Hambrick GW Jr, Shulman LE. Papular mucinosis: a clinicopathological study of four patients. Arch Dermatol. 1982; 118: 9-13
30. Donald GF, Hensley WJ, McGovern VJ. Lichen myxedematosus (papular mucinosis): a brief review of the literature and report of a case which failed to respond to ACTH and cortisone. Aust J Dermatol. 1953; 2: 28-34
31. Perry HO, Montgomery H, Stickney JM. Further observations on lichen myxedematosus. Ann Intern Med. 1960; 53: 955-969
32. Dalton JE, Booth BH, Gray HR, Evans PV. Lichen myxedematosus (papular mucinosis). Arch Dermatol. 1961; 83: 92-104
33. Howsden SM, Herndon JH Jr, Freeman RG. Lichen myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol. 1975; 111: 1325-1330
34. Liden S, Westermark P, Hilden JO, et al. Lichen myxedematosus with generalized nodular panniculitis. Acta Derm Venereol. 1971; 51: 273-278
35. Aberer W, Wolff K. Skleromyxödem: immunsuppressive Therapie mit Zyklophosphamid. Hautarzt. 1988; 39: 277-280
36. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988; 19: 469-477
37. Brenner S, Yust I. Treatment of scleromyxedema with etretinate. J Am Acad Dermatol. 1984; 10: 295-296
38. Berkson M, Lazarus GS, Uberti-Benz M, Rook AH. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol. 1991; 25: 724
39. Krasagakis K, Zouboulis CC, Owsianowski M, et al. Remission of scleromyxedema following treatment with extracorporeal photophoresis. Br J Dermatol. 1996; 135: 463-466
40. McCarthy JR, Osserman E, Lombardo PC, Takatsuki K. An abnormal serum globulin in lichen myxedematosus. Arch Dermatol. 1964; 89: 446-450
41. MacFarlane AW, Davenport A, Verbov JL, et al. Scleromyxedema: successful treatment with plasma exchange and immunosuppression. Br J Dermatol. 1987; 117: 653-657
42. Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxedema. Arch Dermatol. 1987; 123: 786-789
43. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993; 36: 75-83
44. Ikeada H, Fujiwara K. Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. Hepatol. 1995; 21: 1161-1166
45. Iranzo P, Lopez-Lerma I, Blade J, Rovira M, Herrero C. Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol. 2007; 21: 129-130
46. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001; 137: 1071-1072
47. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005; 141: 1277-1282
48. Illa I, de la Torre C, Rojas-Garcia R, Altes A, Blesa R, Sierra J, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood. 2006; 108: 773-774
49. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-Term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine. 2008; 87: 10-20
50. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxedema with high-dose intravenous immunoglobulin. Clin Exp Dermatol. 2004; 29: 317-318
51. Kulczycki A, Nelson M, Eisen A, Heffenan M. Scleromyxedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol. 2003; 149: 1267-1281
52. Lister RK, Jolles S, Whittaker S, Black C, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIG). J Am Acad Dermatol. 2000; 43: 403-408
53. Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxedema. Ann Rheum Dis. 2002; 61: 59-61
54. Rongioletti F, Merlo G, Cinotti E, Fausti V, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013, E-pub ahead of print